This bill amends section 340B of the Public Health Service Act to reinforce access to discounted outpatient drugs for covered entities and to confirm that covered entities may use contract pharmacies to dispense 340B-purchased drugs. It also narrows the scope of permissible manufacturer conditions on 340B purchases.
The bill matters because it formalizes longstanding practices used by safety-net hospitals, community health centers, and clinics to obtain specialty and mail-order drugs for patients through third-party pharmacies, while creating clearer enforcement tools against manufacturers that attempt to limit access or impose atypical contractual conditions.
At a Glance
What It Does
Amends 340B(a) to add a provision that prohibits manufacturers from placing certain conditions on purchases of covered outpatient drugs and adds an explicit paragraph saying the 340B requirements apply when covered entities contract with pharmacies. It also amends 340B(d) to authorize civil monetary penalties for intentional non‑overcharge violations and to require HHS rulemaking for enforcement and claims processes.
Who It Affects
Safety-net providers that participate in 340B (e.g., disproportionate share hospitals, federally qualified health centers, Ryan White clinics) and pharmacies that contract with them; brand drug manufacturers who have 340B obligations; and HHS (which gains new regulatory and enforcement duties).
Why It Matters
The measure reduces legal ambiguity about contract-pharmacy arrangements and limits manufacturers’ leverage to condition or block shipments, while increasing manufacturers’ exposure to financial sanctions—potentially shifting negotiation dynamics, distribution practices for specialty drugs, and HHS administrative workload.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill makes three concrete kinds of changes to the statutory 340B framework. First, it inserts a new subparagraph into the definition of the manufacturer obligations under 340B(a) that does two things in the statute’s text: (1) restates that manufacturers must offer covered outpatient drugs at or below the statutory ceiling price regardless of how or where those drugs are dispensed; and (2) lists categories of contractual or operational conditions that manufacturers may not impose on covered entities when those entities buy discounted drugs.
The listed prohibitions cover limitations on delivery or where a drug can be dispensed, limits on purchase mechanisms, requirements for assurances of compliance, and demands for claims data or other information that go beyond customary business practices. The bill also makes those prohibitions subject to Secretary approval for any conditions the manufacturer asserts are permitted.
Second, the bill adds an explicit paragraph saying the 340B(a) duties and prohibitions apply when a covered entity elects to contract with one or more pharmacies to dispense 340B-purchased drugs to the covered entity’s patients. That text removes statutory ambiguity about whether 340B discounts attach when a third-party pharmacy dispenses the drug on behalf of a covered entity and ties the same manufacturer responsibilities to contract-pharmacy arrangements.Third, the bill strengthens enforcement.
It amends the enforcement subsection to authorize civil monetary penalties for intentional violations of the new prohibitions (distinct from overcharge remedies). The statute sets an upper limit on penalties (up to $2,000,000 per day for each day of violation) and directs the Secretary of Health and Human Services to issue regulations establishing assessment standards.
The statute also adds a regulatory deadline: the Secretary must promulgate implementing regulations within 180 days to operationalize (A) standards and procedures for assessing penalties and (B) a process under which covered entities may assert claims of violations under the amended 340B provisions. Together, the statutory edits both make the manufacturer prohibitions explicit and provide HHS with a civil‑penalty tool and a claims pathway to remedy non‑overcharge abuses.
The Five Things You Need to Know
The bill inserts a new prohibited-conditions clause into 340B(a) that expressly bars manufacturer requirements that limit delivery locations, restrict purchase mechanisms, demand non-customary data submissions, or require pre-approval assurances.
It adds paragraph (11) to 340B(a) making the statute’s requirements and prohibitions apply when a covered entity contracts with one or more pharmacies to dispense drugs purchased at 340B pricing.
The amendments create a civil monetary penalty authority for intentional violations (other than overcharges) with an explicit statutory cap of up to $2,000,000 per day for each day of violation.
The Secretary of Health and Human Services must promulgate regulations within 180 days after enactment to set standards for assessing those penalties.
The Secretary must also issue regulations within 180 days to permit covered entities to assert claims of violations under the 340B enforcement process described in the statute.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Gives the bill its public name: the 340B Pharmaceutical Access To Invest in Essential, Needed Treatments & Support Act of 2025 (340B PATIENTS Act of 2025). This is a caption-only provision with no operational effect.
Findings and purposes
Sets out Congress’s findings about the 340B program’s role in stretching provider resources, the historical use of contract pharmacies (including to access specialty and mail-order drugs), and the program’s contribution to lowering Part D spending. The purposes clause frames the rest of the bill: to clarify manufacturers’ obligations, bar conditions that limit covered entities’ use of discounts, and affirm contract-pharmacy dispensing.
Prohibited manufacturer conditions; explicit contract-pharmacy coverage
Amends paragraph (1) of 340B(a) by adding an express prohibition on manufacturer-imposed conditions that would limit delivery, methods of purchase, locations of dispensing/administration, require compliance assurances, or force non-customary data submissions. The amendment also inserts a new paragraph (11) to declare that the paragraph (1) requirements and prohibitions apply when covered entities contract with pharmacies to dispense 340B drugs. Practically, the statutory language constrains manufacturers from refusing to ship to a pharmacy designated by a covered entity or from inserting novel contractual data- or process-requirements that single out covered entities.
New civil-penalty authority and claims process rulemaking
Adds a subclause authorizing civil monetary penalties for intentional violations of the newly added prohibitions (distinct from overcharge remedies). The statute specifies an upper cap of $2,000,000 per day, requires the Secretary to adopt standards in regulation within 180 days, and directs that penalties may continue each day until the violation is cured. It also requires HHS rulemaking within 180 days to permit covered entities to bring claims under the administrative process set out in the statute’s enforcement paragraph, operationalizing how entities invoke remedies for manufacturer misconduct.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Federally qualified health centers and community clinics — The bill affirms their ability to use third‑party pharmacies to obtain and dispense specialty and mail-order drugs, preserving access pathways often essential for patients with chronic or complex conditions.
- Safety‑net hospitals (including disproportionate share hospitals) — By restricting manufacturers’ ability to impose location or delivery limits, hospitals retain flexibility to deploy 340B savings through contract-pharmacy networks that support outpatient programs and patient assistance.
- Patients served by covered entities — Patients dependent on specialty drugs or mail-order delivery are less likely to face disrupted access if manufacturers cannot block shipments or impose atypical conditions.
Who Bears the Cost
- Brand drug manufacturers — They face new enforcement exposure (civil monetary penalties up to statutory caps) and restrictions on contracting practices previously used to control distribution.
- Pharmacies that sell into both commercial and 340B channels — They may face operational changes as manufacturers recalibrate distribution controls; pharmacies could also absorb compliance burdens tied to serving as contract partners.
- HHS/HRSA (administrative side) — The agency must issue two sets of regulations within 180 days and implement processes for adjudicating claims and assessing penalties, creating an unfunded regulatory and enforcement workload.
Key Issues
The Core Tension
The bill forces a trade-off between preserving access for safety‑net providers (by limiting manufacturers’ distribution controls) and preserving manufacturers’ ability to manage distribution, prevent diversion, and protect commercial channels; resolving that tension depends on regulatory detail about what constitutes legitimate business practice versus discriminatory conditions.
The bill clarifies statutory language and creates enforcement tools, but it leaves several operational questions unresolved. The prohibition lists categories of disallowed conditions but uses terms like “customary business practices” and requires Secretary approval for non-prohibited conditions; those standards will be fact-intensive and hinge on regulatory definitions.
Manufacturers and covered entities will dispute what counts as customary or disproportionate impact; HHS rulemaking will be asked to draw lines that affect commercial contracting and supply-chain risk management.
The penalty structure is blunt: an explicit statutory per‑day cap creates pressure to remedy violations quickly, but the mechanics of notice, intent-proof, mitigation credits, or the interplay with existing overcharge remedies are delegated to forthcoming regulations. The 180‑day rulemaking clock is short for crafting detailed adjudicatory procedures, evidentiary standards, and processes to address supply‑chain complexities for specialty drugs.
Finally, although the statute affirms contract pharmacies, it does not create a new registration, audit standard, or data-exchange protocol; the absence of detailed operational controls means disputes over auditing, recordkeeping, and patient attribution will likely migrate to the administrative process and to litigation.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.